Growth factor which acts through erb b-4 rtk
AssigneeYeda Research and Development Co. Ltd.
InventorsDaniel Harari, Yosef Yarden
Life of this patent
Estimating the term…
Abstract
A novel ErbB-4 ligand, referred to herein as Neuregulin-4 (NRG-4) is disclosed as well as polynucleotide sequences encoding NRG-4, oligonucleotides and oligonucleotide analogs derived from polynucleotide sequences, a display library displaying short peptides derived from NRG-4, antibodies recognizing NRG-4, peptides or peptide analogs derived from NRG-4, and pharmaceutical compositions and methods of employing peptides or peptide analogs, oligonucleotides and oligonucleotide analogs, and/or polynucleotide sequences to up-regulate or down-regulate ErbB-4 receptor activity (signaling).
Claims3
An antibody or antibody fragment capable of specifically recognizing a polypeptide at least 95% homologous to positions 4–50 of SEQ ID NO:
- 2 as determined using the BestFit software of the Wisconsin sequence analysis package, utilizing the Smith and Waterman algorithm, where gap creation penalty equals 8 and gap extension penalty equals 2, said polypeptide being capable of binding ErbB-4.
An antibody or an antibody fragment capable of specifically recognizing positions 4–50 of SEQ ID NOs:2.
Dependencies are inferred from the claim text.